This event was organised and sponsored by Sanofi
Alessandro Lucchesi reports consultancy roles with Amgen, AOP, Grifols, Incyte, Morphosys, Novartis, Protagonist, Sanofi, and SOBI. He has participated in speaker bureaus for Amgen, Bristol Myers Squibb, Grifols, Incyte, Novartis, Pfizer, Recordati, Sanofi, and SOBI.
María Eva Mingot-Castellano reports research funding and consulting fees from Amgen, Argenx, Grifols, Novartis, Novo Nordisk, Sanofi, SOBI, and Takeda. She is also a member of several committees, including the Scientific Director Committee of SEHH (Spanish Society of Hematology and Hemotherapy), Director Committee of Fundación Victoria Eugenia, Director Committee of CAT (Transfusion Quality Director Committee), and Director Committee of GEPTI (Spanish ITP Group), and serves as Coordinator of REPTT (Spanish and Portuguese TTP registry).
Waleed Ghanima reports fees for participation in advisory boards from Argenx, Alpine, Amgen, Cellphire, Grifols, HiBio, Hutchmed, Kedrion, Novartis, Pfizer, Principia Biopharma Inc., Sanofi, SOBI, Takeda, and UCB. He has received lecture honoraria from Amgen, Bayer, Bristol Myers Squibb, Grifols, Novartis, Pfizer, Sanofi, and SOBI, and research grants from Bayer, Bristol Myers Squibb, Janssen, Pfizer, Sanofi, SOBI, and UCB.
Content description: This symposium explores the evolving understanding of immune dysregulation in immune thrombocytopenia (ITP) and warm antibody autoimmune hemolytic anemia (wAIHA), with a focus on shared pathophysiological mechanisms and their clinical implications. Leading hematology experts discuss how targeting multiple immune pathways may represent a new paradigm in treating these conditions.
Topics covered:
- Immunological drivers of autoimmune cytopenias, including the role of the NLRP3 inflammasome, NF-κB signaling, and innate-adaptive immune crosstalk
- The impact of immune dysregulation on clinical outcomes, including fatigue, thrombosis, infections, and quality of life in ITP and wAIHA
- Current treatment landscape for ITP and wAIHA, including corticosteroids, TPO receptor agonists, rituximab, and fostamatinib
- Emerging therapies and their mechanisms, including BTK inhibitors, anti-CD38 agents, anti-BAFF/APRIL agents, and FcRn inhibitors
- The role of rilzabrutinib and multi-immune modulation as a potential new therapeutic approach in both conditions
MAT-GLB-2601908 – 1.0 – 04/2026
Speakers:
Waleed Ghanima
Østfold Hospital and University of Oslo, Oslo, Norway
Alessandro Lucchesi
Romagna Institute for the Study of Tumors, Meldola, Italy
María Eva Mingot-Castellano
Virgen del Rocío University Hospital, Sevilla, Spain
